104 related articles for article (PubMed ID: 1740372)
21. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy.
Stern WH; Lewis GP; Erickson PA; Guerin CJ; Anderson DH; Fisher SK; O'Donnell JJ
Am J Ophthalmol; 1983 Jul; 96(1):33-42. PubMed ID: 6869478
[TBL] [Abstract][Full Text] [Related]
22. Taxol for the treatment of proliferative vitreoretinopathy.
van Bockxmeer FM; Martin CE; Thompson DE; Constable IJ
Invest Ophthalmol Vis Sci; 1985 Aug; 26(8):1140-7. PubMed ID: 2862129
[TBL] [Abstract][Full Text] [Related]
23. Ocular toxicity of intravitreal tacrolimus.
Passos E; Genaidy MM; Peyman GA
Ophthalmic Surg Lasers; 2002; 33(2):140-4. PubMed ID: 11942546
[TBL] [Abstract][Full Text] [Related]
24. Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye.
Hida T; Chandler DB; Sheta SM
Graefes Arch Clin Exp Ophthalmol; 1987; 225(4):303-7. PubMed ID: 3653728
[TBL] [Abstract][Full Text] [Related]
25. Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes.
Albini TA; Abd-El-Barr MM; Carvounis PE; Iyer MN; Lakhanpal RR; Pennesi ME; Chevez-Barrios P; Wu SM; Holz ER
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):390-5. PubMed ID: 17197559
[TBL] [Abstract][Full Text] [Related]
26. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye.
Connor TB; Roberts AB; Sporn MB; Danielpour D; Dart LL; Michels RG; de Bustros S; Enger C; Kato H; Lansing M
J Clin Invest; 1989 May; 83(5):1661-6. PubMed ID: 2708527
[TBL] [Abstract][Full Text] [Related]
27. [Antiproliferative effect of sustained drug delivery system of all-trans retinoic acid implant into rabbit's vitreous cavity for treatment of proliferative vitreoretinopathy].
Yan XR; Dong XG; Chen N; Wang W
Zhonghua Yan Ke Za Zhi; 2003 Oct; 39(10):621-5. PubMed ID: 14766078
[TBL] [Abstract][Full Text] [Related]
28. Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Proctor lecture.
Machemer R
Invest Ophthalmol Vis Sci; 1988 Dec; 29(12):1771-83. PubMed ID: 3056866
[No Abstract] [Full Text] [Related]
29. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
Liou GI; Pakalnis VA; Matragoon S; Samuel S; Behzadian MA; Baker J; Khalil IE; Roon P; Caldwell RB; Hunt RC; Marcus DM
Mol Vis; 2002 Dec; 8():494-501. PubMed ID: 12500176
[TBL] [Abstract][Full Text] [Related]
30. Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin.
Kumar A; Tewari HK; Bathwal DP; Khosla PK
Indian J Ophthalmol; 1994 Mar; 42(1):31-5. PubMed ID: 7927629
[TBL] [Abstract][Full Text] [Related]
31. Measurement of cellular proliferation within the vitreous during experimental proliferative vitreoretinopathy.
Yang CM; Olsen KR; Hernandez E; Cousins SW
Graefes Arch Clin Exp Ophthalmol; 1992; 230(1):66-71. PubMed ID: 1547971
[TBL] [Abstract][Full Text] [Related]
32. Breakdown of the blood-retinal barrier after radiofrequency-induced ocular hyperthermia.
Kiryu J; Ogura Y; Moritera T; Yoshimura N; Honda Y
Ophthalmologica; 1993; 206(2):107-10. PubMed ID: 8272325
[TBL] [Abstract][Full Text] [Related]
33. Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.
Steinhorst UH; Hatchell DL; Chen EP; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1993 Oct; 231(10):591-4. PubMed ID: 8224935
[TBL] [Abstract][Full Text] [Related]
34. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy.
Arroyo MH; Refojo MF; Araiz JJ; Tolentino FI; Cajita VN; Elner VM
Retina; 1993; 13(3):245-50. PubMed ID: 8235109
[TBL] [Abstract][Full Text] [Related]
35. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.
Chandler DB; Rozakis G; de Juan E; Machemer R
Am J Ophthalmol; 1985 Jun; 99(6):686-90. PubMed ID: 2409802
[TBL] [Abstract][Full Text] [Related]
36. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil.
Rubsamen PE; Davis PA; Hernandez E; O'Grady GE; Cousins SW
Arch Ophthalmol; 1994 Mar; 112(3):407-13. PubMed ID: 8129669
[TBL] [Abstract][Full Text] [Related]
37. The lack of an effect of intraocular steroids on irradiated fibroblasts in experimental proliferative vitreoretinopathy.
Chandler DB; Hida T; Rozakis G; Forbes VS; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1992; 230(2):188-91. PubMed ID: 1577303
[TBL] [Abstract][Full Text] [Related]
38. Expression of growth factor mRNA in rabbit PVR model systems.
Planck SR; Andresevic J; Chen JC; Holmes DL; Rodden W; Westra I; Wu SC; Huang XN; Kay G; Wilson DJ
Curr Eye Res; 1992 Nov; 11(11):1031-9. PubMed ID: 1282856
[TBL] [Abstract][Full Text] [Related]
39. Induction of experimental proliferative vitreoretinopathy in the rabbit eye by intravitreal injections of fibroblast growth factor.
Baudouin C; Fredj-Reygrobellet D; Ettaiche M; Barritault D; Gastaud P; Lapalus P
Lens Eye Toxic Res; 1992; 9(3-4):505-11. PubMed ID: 1284520
[No Abstract] [Full Text] [Related]
40. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.
Hui YN; Liang HC; Cai YS; Kirchhof B; Heimann K
Graefes Arch Clin Exp Ophthalmol; 1993 Feb; 231(2):109-14. PubMed ID: 8444357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
